This site is intended for healthcare professionals
Drug information

Metoclopramide

POM
Read time: 10 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Paediatric population:

Metoclopramide 5 mg/ml Injection is indicated in children (1 – 18 years) for:

• Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option

• Treatment of established post-operative nausea and vomiting (PONV) as a second line option

For other indications, the use in the paediatric population is not recommended.

Adult population:

Metoclopramide 5 mg/ml Injection is indicated in adults for:

• Prevention of post-operative nausea and vomiting (PONV)

• Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting

• Prevention of radiotherapy induced nausea and vomiting (RINV)

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).